Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 96.50B |
| Revenue (ttm) | 45.74B |
| Net Income (ttm) | 9.13B |
| Shares Out | 1.22B |
| EPS (ttm) | 7.36 |
| PE Ratio | 15.37 |
| Forward PE | 9.67 |
| Dividend | 3.92 (4.95%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 903,854 |
| Average Volume | 1,938,941 |
| Open | 79.69 |
| Previous Close | 79.13 |
| Day's Range | 79.54 - 81.05 |
| 52-Week Range | 76.68 - 110.88 |
| Beta | 0.44 |
| RSI | 40.49 |
| Earnings Date | Oct 24, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Sanofi (SNY) Gains Morgan Stanley Upgrade Amid Promising Drug Data
Sanofi (SNY) Gains Morgan Stanley Upgrade Amid Promising Drug Data
Sanofi upgraded at Morgan Stanley on potential of amlitelimab vs. Dupixent
Morgan Stanley upgrades Sanofi to overweight after strong amlitelimab data for eczema. Read more here.
Morgan Stanley Upgrades Sanofi (SNY) to Overweight, Raises Price Target | SNY Stock News
Morgan Stanley Upgrades Sanofi (SNY) to Overweight, Raises Price Target | SNY Stock News
This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Notable healthcare headlines for the week: Novartis, Cigna and Sanofi in focus
Get the latest S&P 500 healthcare sector updates, market movers, and key pharma deals.
Today's moving stocks: American Eagle, Figma, T. Rowe Price, Amazon, Sanofi
Here are the stocks making the biggest moves on Sept. 4, 2025
Sanofi (SNY) Shares Drop Following Eczema Drug Trial Results
Sanofi (SNY) Shares Drop Following Eczema Drug Trial Results
Sanofi market value tanks following weak results on eczema drug trials
Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab...
Why Is Sanofi Stock Falling Thursday?
On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fre...
Why Is Sanofi Stock Falling Thursday?
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential. Latest Ratings for ... Full story available on...
Sanofi Drops As Eczema Drug Faces Big Test
Sanofi Drops As Eczema Drug Faces Big Test
European Stocks Rise Amid Bond Market Stability; Sanofi (SNY) Falls on Drug Trial Results
European Stocks Rise Amid Bond Market Stability; Sanofi (SNY) Falls on Drug Trial Results
Sanofi Drops As Eczema Drug Faces Big Test(EDIT)
Sanofi Drops As Eczema Drug Faces Big Test(EDIT)
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
French drugmaker Sanofi SA (NASDAQ: SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match inves...
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
French drugmaker Sanofi SA SNY stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expecta...
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.
Sanofi falls after late-stage trial data for eczema therapy
Sanofi Shares Sink as Experimental Drug Results Disappoint
Sanofi shares plunged at the market open Thursday as results from a late-stage trial of its experimental drug to treat skin conditions disappointed investors.
Sanofi shares sink over 9% on weak trial results for experimental inflammation drug
Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its experimental inflammatory disease drug amlitelimab fell short of Wall Street expectations.
Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial
Amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and adults with atopic dermatitis.
Press Release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Press Release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, de...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Sanofi (SNY) Receives Upgrade from Deutsche Bank | SNY Stock News
Sanofi (SNY) Receives Upgrade from Deutsche Bank | SNY Stock News
Sanofi CEO: AI might beat IQ, not EQ — but never say never
We underestimate the scale of the AI learning curve, says Paul Hudson, CEO of Sanofi.